Skip to content

CYCLO THERAPEUTICS, INC.: 10-K filed 2023-03-17

What CYCLO THERAPEUTICS, INC. reported in its annual report filed 2023-03-17 (fiscal FY 2022): 33 published measures, 67 facts as tagged in accession 0001437749-23-007064.

This filing

Form
10-K (annual report)
Filed
2023-03-17
Fiscal period
fiscal FY 2022
Accession
0001437749-23-007064 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-12-314,215,213USD
At 2021-12-3119,520,833USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-12-31734,544USD
At 2021-12-3115,671,863USD
At 2020-12-3110,452,482USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-12-311,543,418USD
At 2021-12-3116,612,711USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,450,888USD365
2021-01-01 to 2021-12-31-14,286,655USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,114,241USD365
2021-01-01 to 2021-12-31-15,005,298USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2022-01-01 to 2022-12-3115,086USD365
2021-01-01 to 2021-12-3122,500USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-12-316,778USD365
2021-01-01 to 2021-12-3118,757,074USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-01-01 to 2022-12-3138,170USD365
2021-01-01 to 2021-12-3114,822USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-12-31-63,799,379USD
At 2021-12-31-48,348,491USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2022-01-01 to 2022-12-318,439,177shares365
2021-01-01 to 2021-12-316,370,073shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-1.83USD/shares365
2021-01-01 to 2021-12-31-2.24USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2022-12-3155,188USD
At 2021-12-3159,583USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-01-01 to 2022-12-31354,056USD365
2021-01-01 to 2021-12-31295,578USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,621,886USD365
2021-01-01 to 2021-12-31-14,290,060USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-12-314,158,555USD
At 2021-12-3119,436,335USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-12-313,480,669USD
At 2021-12-313,830,936USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2022-12-3154,991USD
At 2021-12-31493,113USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2022-12-31254,491USD
At 2021-12-31227,437USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-01-01 to 2022-12-318,999,543USD365
2021-01-01 to 2021-12-319,153,780USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-12-318,481,848shares
At 2021-12-318,403,869shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-12-3164,533,074USD
At 2021-12-3164,019,513USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2022-12-311,470USD
At 2021-12-3117,636USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2022-12-31156,727USD
At 2021-12-31141,641USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2022-12-31101,539USD
At 2021-12-3182,058USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2022-12-314,000USD
At 2021-12-3183,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-15,450,888USD365
2021-01-01 to 2021-12-31-14,286,655USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2022-01-01 to 2022-12-3119,481USD365
2021-01-01 to 2021-12-3116,827USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2022-01-01 to 2022-12-3119,481USD365
2021-01-01 to 2021-12-3116,827USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2022-01-01 to 2022-12-3112,474USD365
2021-01-01 to 2021-12-31-3,405USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2022-01-01 to 2022-12-310USD365
2021-01-01 to 2021-12-313,525USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-427,850USD365
2021-01-01 to 2021-12-31444,023USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-3127,054USD365
2021-01-01 to 2021-12-31-10,472USD365

Inspect the source

Entity
CYCLO THERAPEUTICS, INC. / CIK 0000922247
Captured
2026-09-21T17:17:43.874Z
SEC response SHA-256
00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))